Welcome to our dedicated page for Ventyx Biosciences news (Ticker: VTYX), a resource for investors and traders seeking the latest updates and insights on Ventyx Biosciences stock.
Ventyx Biosciences, Inc. news covers the company’s history as a Nasdaq-listed clinical-stage biopharmaceutical issuer developing oral small-molecule therapies for autoimmune, inflammatory, cardiovascular and neurodegenerative diseases. Recurring updates include NLRP3 inhibitor programs such as VTX2735 for recurrent pericarditis and VTX3232 for inflammation-related cardiovascular and neurodegenerative indications, as well as inflammatory bowel disease candidates tamuzimod (VTX002) and VTX958.
Company announcements also address clinical data, trial planning, advisory board changes, investor conference participation, operating and financial results, material agreements, shareholder voting matters and the completed acquisition that made Ventyx a wholly owned subsidiary of Eli Lilly and Company.
Ventyx Biosciences priced its upsized IPO at $16.00 per share, offering 9,472,656 shares, which is expected to generate approximately $151.5 million in gross proceeds. The underwriters also have a 30-day option to purchase an additional 1,420,898 shares. Trading on the Nasdaq under the ticker symbol VTYX is set to commence on October 21, 2021, with the offering closing on October 25, 2021. Jefferies, Evercore ISI, and Piper Sandler are the joint book-running managers for this offering.
Ventyx Biosciences has appointed Dr. Sheila Gujrathi as Executive Chair and Dr. Jörn Drappa as Chief Medical Officer, enhancing its leadership in developing therapies for autoimmune diseases. The company successfully closed a $51.0 million Series B financing round led by Surveyor Capital. This funding aims to accelerate the advancement of its clinical pipeline, which includes product candidates targeting inflammatory diseases. Notable board additions include William White and Luisa Salter-Cid, enriching the company's business and scientific expertise.